Status: Recruiting
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).
Participants needed: 50
Trial details
Biological sex: AllType: ObservationalSponsor: Sanofi Pasteur, a Sanofi CompanyUpdated: Dec 1, 2025Locations: 1Duration: 22 Months
Eligibility criteria
Sufficient evidence to confirm that vaccination occurred during the pregnancy or... [+1]